EMA
approval
· 2026-01-28
EMA Authorised: Pomalidomide Teva (Pomalidomide) — Teva GmbH
Summary
EMA has authorised Teva GmbH's pomalidomide product for the treatment of multiple myeloma; decision date 28 January 2026.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Teva GmbH. Decision date: 28/01/2026